- Home
- RGR vs PRAX Comparison
RGR vs PRAX Comparison
Compare RGR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGR
- PRAX
- Stock Information
- Founded
- RGR 1949
- PRAX 2015
- Country
- RGR United States
- PRAX United States
- Employees
- RGR N/A
- PRAX N/A
- Industry
- RGR Ordnance And Accessories
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- RGR Industrials
- PRAX Health Care
- Exchange
- RGR Nasdaq
- PRAX Nasdaq
- Market Cap
- RGR 616.8M
- PRAX 599.7M
- IPO Year
- RGR N/A
- PRAX 2020
- Fundamental
- Price
- RGR $35.84
- PRAX $51.18
- Analyst Decision
- RGR
- PRAX Strong Buy
- Analyst Count
- RGR 0
- PRAX 10
- Target Price
- RGR N/A
- PRAX $101.00
- AVG Volume (30 Days)
- RGR 189.4K
- PRAX 279.6K
- Earning Date
- RGR 07-30-2025
- PRAX 08-12-2025
- Dividend Yield
- RGR 1.96%
- PRAX N/A
- EPS Growth
- RGR N/A
- PRAX N/A
- EPS
- RGR 1.83
- PRAX N/A
- Revenue
- RGR $534,561,000.00
- PRAX $8,122,000.00
- Revenue This Year
- RGR N/A
- PRAX N/A
- Revenue Next Year
- RGR $1.89
- PRAX $6,358.50
- P/E Ratio
- RGR $19.56
- PRAX N/A
- Revenue Growth
- RGR 0.65
- PRAX 270.02
- 52 Week Low
- RGR $32.74
- PRAX $26.70
- 52 Week High
- RGR $46.40
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- RGR 43.95
- PRAX 69.52
- Support Level
- RGR $35.53
- PRAX $45.70
- Resistance Level
- RGR $36.82
- PRAX $48.00
- Average True Range (ATR)
- RGR 0.76
- PRAX 2.23
- MACD
- RGR -0.04
- PRAX 0.35
- Stochastic Oscillator
- RGR 17.27
- PRAX 95.91
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.